Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood protein predict better diabetes treatment?

NCT ID NCT07539584

Knowledge-focused Sponsor: Moscow Regional Research and Clinical Institute (MONIKI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study in 130 adults with type 2 diabetes and fatty liver disease tested whether a blood marker called adiponectin can predict how well certain diabetes drugs reduce liver fat. Participants received either an SGLT2 inhibitor, a GLP-1 receptor agonist, or both for six months. The goal was to see if changes in adiponectin levels matched improvements in liver health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT2 inhibitors (dapagliflozin or empagliflozin) and GLP-1 receptor agonists
What this could lead to
If successful, this could help doctors predict which diabetes medications best reduce liver fat in patients with fatty liver disease.
What could go wrong
This is a small, completed study focused on a biomarker, not a treatment outcome. Results may not lead to new therapies or apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

130 people

The number who actually took part.

Started

Mar 2022

Finished

Apr 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent of the patient to participate in the study * Glycated hemoglobin level exceeding the target by no more than 1%. * Age 40 to 65 years inclusive * Verified diagnosis of MAFLD, according to the criteria of EASL 2020, * Confirmed diagnosis of type 2 diabetes mellitus * Body mass index (BMI) 25-39.9 kg/m2 * Refusal to take any dietary supplements Non-inclusion criteria: * Chronic alcohol abuse (alcoholic fatty liver disease) * Insulin-dependent diabetes * Use of hepatoprotective agents * High risk of atherosclerotic cardiovascular disease (age \> 55 years with coronary, carotid, or lower extremity artery stenosis, or left ventricular hypertrophy) * Chronic kidney disease * Chronic heart failure Exclusion Criteria: * Patient withdrawal of consent * Pregnancy (if applicable) * Decompensation of diabetes during therapy * Development of adverse events associated with therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated fatty liver disease (mafld) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated fatty liver disease (mafld) Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Moscow Regional Research and Clinical Institute

    Moscow, 129110, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.